
Article in Japanese
A case of drug-induced lung injury caused by sitagliptin
Tetsuya Hanakaa,b Tomotoshi Imanagaa Satoru Kawakamia Hiromi Idea Atsushi Moriwakia Hiroshi Mukaeb
aDepartment of Respiratory Medicine, Steel Memorial Yawata Hospital
bDepartment of Respiratory Medicine, University of Occupational and Environmental Health, Japan
A 63-year-old woman presented to our hospital with a 13-day history of nonproductive cough that had progressively worsened. She was quite hypoxemic, and her chest computed tomography revealed diffuse ground-glass opacities in both lungs. She had type 2 diabetes mellitus and had been taking sitagliptin 16 days earlier. Stains and cultures of bronchoscopic specimens for bacteria, fungi, and acid-fast bacilli were negative; moreover, all other infectious examinations were also negative. Thus we diagnosed her as drug-induced lung injury with sitagliptin by positive response to a drug-induced lymphocyte stimulation test. Although she required mechanical ventilation for progressive respiratory failure a day after admission, she was recovered within a couple of days soon after an initiation of treatment with prednisolone. The dipeptidyl peptidase-4 (DPP-4) inhibitors are widely adopted in diabetes mellitus therapy. It should be noted that DPP-4 inhibitors may cause lung injury.
Sitagliptin Drug-induced lung injury Drug-induced lymphocyte stimulation test Dipeptidyl peptidase-4 inhibitor KL-6
Received 23 Jan 2014 / Accepted 18 Mar 2014
AJRS, 3(4): 594-598, 2014